Lauroylated Histidine-Enriched S4-PV Peptide as an Efficient Gene Silencing Mediator in Cancer Cells
Pharmaceutical Research, ISSN: 1573-904X, Vol: 37, Issue: 10, Page: 188
2020
- 7Citations
- 5Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations7
- Citation Indexes7
- CrossRef1
- Captures5
- Readers5
Article Description
Purpose: This study aimed to endow the cell-penetrating peptide (CPP) S4-PV with adequate features towards a safe and effective application in cancer gene therapy. Methods: Peptide/siRNA complexes were prepared with two new derivatives of the CPP S4-PV, which combine a lauroyl group attached to the N- or C-terminus with a histidine-enrichment in the N-terminus of the S4-PV peptide, being named C12-H-S4-PV and H-S4-PV-C12, respectively. Physicochemical characterization of siRNA complexes was performed and their cytotoxicity and efficiency to mediate siRNA delivery and gene silencing in cancer cells were assessed in the absence and presence of serum. Results: Peptide/siRNA complexes prepared with the C12-H-S4-PV derivative showed a nanoscale (ca. 100 nm) particle size, as revealed by TEM, and efficiently mediated gene silencing (37%) in human U87 glioblastoma cells in the presence of 30% serum. In addition, the new C12-H-S4-PV-based siRNA delivery system efficiently downregulated stearoyl-CoA desaturase-1, a key-enzyme of lipid metabolism overexpressed in cancer, which resulted in a significant decrease in the viability of U87 cells. Importantly, these complexes were able to spare healthy human astrocytes. Conclusions: These encouraging results pave the way for a potential application of the C12-H-S4-PV peptide as a promising tool in cancer gene therapy.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85090147228&origin=inward; http://dx.doi.org/10.1007/s11095-020-02904-x; http://www.ncbi.nlm.nih.gov/pubmed/32888084; https://link.springer.com/10.1007/s11095-020-02904-x; https://dx.doi.org/10.1007/s11095-020-02904-x; https://link.springer.com/article/10.1007/s11095-020-02904-x
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know